New lung drug faces off against standard treatment in major trial
Disease control
Not yet recruiting
This study tests a new drug, LYT-100, against an existing one (pirfenidone) for idiopathic pulmonary fibrosis, a lung disease that gets worse over time. About 1,100 adults will take either drug three times daily for up to a year, and researchers will measure how well their lungs …
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC